Scribe Sets Terms for a $100 Million IPO

Company Scribe Therapeutics Event Type IPO / Public Offering Modality In Vivo CRISPR Epigenetic Silencing (ELXR Platform, LNP Delivery) Asset STX-1150 Target PCSK9 Disease Area Atherosclerotic Cardiovascular Disease / Elevated LDL-C Summary Scribe Therapeutics set terms for an initial public offering of 7.15 million shares…